X

Trial Profile

A proof-of-concept trial with ilixadencel in the broader group of soft tissue sarcomas

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ilixadencel (Primary)
Indications Soft tissue sarcoma
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

15 Mar 2024 According to Mendus media release,company will receive proceeds of up to approximately SEK 90.6 million and company intends to use proceeds from the Warrants to finance the continuation of its operations and extension of cash runway to Q3 2025 including primary analysis of the ilixadencel proof-of-concept trial.
21 Aug 2023 New trial record
16 Aug 2023 According to Mendus media release, the company is currently preparing for a proof-of-concept trial with ilixadencel in the broader group of soft tissue sarcomas in H2 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com